Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88.04), a synthetic a-picoline derivative, administered intravenously
1998

Phase I Study of Penclomedine and Its Neurotoxicity

Sample size: 16 publication Evidence: low

Author Information

Author(s): DI Jodrell, A Bowman, M Stewart, N Dunlop, R French, A MacLellan, J Cummings, JF Smyth

Primary Institution: ICRF Medical Oncology Unit, Western General Hospital, Edinburgh

Hypothesis

What is the maximum tolerated dose (MTD) of penclomedine when administered intravenously?

Conclusion

The study found that the dose-limiting toxicity of penclomedine was dizziness and associated cerebellar ataxia at the maximum dose tested.

Supporting Evidence

  • Neurotoxicity was the dose-limiting toxicity observed in patients.
  • Common toxicity criteria grade II vomiting was recorded at all dose levels.
  • Thirteen out of sixteen patients had received previous chemotherapy.

Takeaway

Doctors tested a new cancer drug called penclomedine on 16 patients to see how much they could safely give without causing serious side effects, but they found that it made some people feel dizzy.

Methodology

This was an open non-randomized study with dose escalation to determine the MTD and toxicity profile of penclomedine.

Limitations

The study was limited by the small sample size and the absence of anti-tumor responses.

Participant Demographics

Eight men and eight women, median age 59 years (range 39-73 years), with good performance status.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication